We determined that the sensitivity, specificity, and AUC for survivin were 52.38%, 86.67%, and 0.603, respectively, while those for fibulin-3 were 100.0%, 93.3%, and 0.994, revealing that fibulin-3 is a more valid biomarker in differentiating MPM from lung cancer. This evidence concerns the gene EFEMP1 and lung carcinoma.